A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landsca ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

Rising rates of metabolic dysfunction–associated steatohepatitis indicate a need for public health interventions.

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

10. Rezdiffra for metabolic dysfunction-associated Steatohepatitis (MASH) Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) was granted FDA approval on March 14, 2024, for the treatment of metabolic ...

By the end of last year, more than 11,800 patients were on Rezdiffra. In a conference call on Wednesday, Madrigal CEO Bill Sibold called the progress “an incredible accomplishment in just nine ...